Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine

ARDSLEY, N.Y.--(BUSINESS WIRE)--

Acorda Therapeutics, Inc. (ACOR) today announced that the Companys Legal department has been selected by Corporate Counsel magazine as one of the four Best Legal Departments 2013.

We are delighted by this honor, said Jane Wasman, Acordas President, International and General Counsel. As a department, we aim to creatively and effectively solve complex legal issues, and much of our success is attributable to strategically partnering with other departments across our organization to advance business objectives in a compliant manner. The growth of our company, and the extensive regulation of the pharmaceutical industry, continually creates new challenges for us to tackle, and we appreciate this recognition of our efforts.

In selecting the Best Legal Departments 2013, Corporate Counsel evaluated a wide range of legal departments across the country and across all industries, including Fortune 500 companies, small start-ups, and not-for-profits.

Ms. Wasman joined Acorda in 2004 as General Counsel. Her team is responsible for all of the Company's legal issues, including such critical areas such as FDA and SEC compliance, interactions with healthcare professionals and payers, intellectual property strategy and prosecution, product development and promotion, and contracts.

The full article on the 2013 Best Legal Departments is available on the Corporate Counsel website at:

http://www.law.com/corporatecounsel/PubArticleCC.jsp?id=1202599233092&Best_Legal_Departments_2013

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with MS, spinal cord injury and other neurological conditions.

Acorda markets AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, in the United States as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an improvement in walking speed. AMPYRA is marketed outside the United States as FAMPYRA (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. AMPYRA and FAMPYRA are manufactured under license from Alkermes Pharma Ireland Limited.

Here is the original post:
Acorda Therapeutics’ Legal Department Recognized on Best Legal Departments List by Corporate Counsel Magazine